Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=-program_reference_codes
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_reference_codes", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-program_reference_codes", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=-program_reference_codes", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=-program_reference_codes" }, "data": [ { "type": "Grant", "id": "11638", "attributes": { "award_id": "5R01MD017364-02", "title": "REDES: a peer network and mobile health (mHealth) enhanced CHW model to maximize COVID-19 vaccination among low income Latinos", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6598, "first_name": "Deborah Elizabeth", "last_name": "Linares", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-13", "end_date": "2026-12-31", "award_amount": 736639, "principal_investigator": { "id": 7157, "first_name": "Kathleen R", "last_name": "Page", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7158, "first_name": "Cui", "last_name": "Yang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1418, "ror": "", "name": "RBHS-SCHOOL OF PUBLIC HEALTH", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic disproportionately impacts Latinos in the US. Failing to provide equitable access to vaccines will exacerbate the profound disparities in COVID-19 and other health conditions among Latinos communities. Our team has established a community coalition and identified effective interventions to reduce disparities among low-income limited English proficiency (LEP) Latino communities using qualitative, survey, and implementation science methodologies. We will test the efficacy of a combination intervention REDES (“Networks”) - a social network and mobile health (mHealth) enhanced community health worker (CHW) intervention - to address COVID-19 vaccine hesitancy and uptake among a cohort of Latinos and their networks in Maryland. We will recruit 300 index participants who have taken the COVID-19 vaccine. Half of the index participants will be randomized to the experimental group (n=150). CHWs will train them to be peer mentors to conduct peer outreach in-person and by text messages and to promote vaccine acceptance and uptake with their networks. Index participants in the control group (n=150) will receive an equal attention intervention. In addition, we will recruit unvaccinated primary and secondary network members of indexes for study participation and COVID-19 vaccination. We will enroll an estimated total of 1,590 primary and secondary network members. All participants will be followed prospectively at 3, 6, 12, and 18 months after baseline intake. The specific aims are: 1) Evaluate the efficacy of a combination intervention REDES to promote COVID-19 vaccine uptake among Latinos; 2) Examine ongoing barriers and facilitators of vaccine uptake among Latinos and their networks to tailor our intervention and address new challenges, and 3) Evaluate the implementation determinants and outcomes of REDES to inform future broad-scale implementation. Our multi-disciplinary research team brings together Latino health, social network, mHealth interventions, vaccine hesitancy expertise; a long-term history of community engagement with partner organizations in Maryland; and existing bilingual/bicultural CHW capacity and a rich local infrastructure for COVID-19 response. If this combination intervention demonstrates the efficacy, we will develop an implementation strategy toolkit, both in English and Spanish, for community partners and health departments interested in replicating the approach. This proposal primarily focuses on COVID-19 vaccination, but knowledge gained will be relevant to future vaccine equity initiatives, such as COVID-19 boosters (if needed) and seasonal influenza vaccination.", "keywords": [ "Address", "Adult", "Appointments and Schedules", "Attention", "Authorization documentation", "Behavioral", "COVID-19", "COVID-19 booster", "COVID-19 disparity", "COVID-19 pandemic", "COVID-19 testing", "COVID-19 vaccination", "COVID-19 vaccine", "Caring", "Clinic", "Communities", "Community Health Aides", "Consolidated Framework for Implementation Research", "Control Groups", "Dizziness", "Dose", "Enrollment", "Evaluation", "Family", "Friends", "Funding", "Future", "Health", "Hospitalization", "Hotlines", "Immigrant", "Immigration", "Individual", "Influenza vaccination", "Infrastructure", "Intake", "Interdisciplinary Study", "Intervention", "Interview", "Knowledge", "Language", "Latino", "Latino Population", "Life", "Limited English Proficiency", "Low income", "Maryland", "Methodology", "Modeling", "Motivation", "Not Hispanic or Latino", "Participant", "Persons", "Policies", "Public Opinion", "RADx Underserved Populations", "Randomized", "Reach Effectiveness Adoption Implementation and Maintenance", "Recommendation", "Recording of previous events", "Reduce health disparities", "Reporting", "Resources", "Respondent", "Sampling", "Social Network", "Structure", "Surveys", "Testing", "Text Messaging", "Touch sensation", "Training", "Trust", "United States National Institutes of Health", "Vaccinated", "Vaccination", "Vaccines", "authority", "behavior change", "bilingualism", "cohort", "community building", "community engagement", "digital", "disparity reduction", "effective intervention", "efficacy evaluation", "efficacy testing", "experimental group", "flexibility", "health literacy", "implementation determinants", "implementation evaluation", "implementation outcomes", "implementation science", "implementation strategy", "indexing", "interest", "mHealth", "marginalization", "member", "outreach", "peer", "peer coaching", "peer networks", "prospective", "recruit", "reinforced behavior", "response", "seasonal influenza", "skills", "success", "theories", "tool", "unvaccinated", "uptake", "vaccine acceptance", "vaccine access", "vaccine hesitancy" ], "approved": true } }, { "type": "Grant", "id": "11639", "attributes": { "award_id": "5R21EB031455-02", "title": "Affinity Reagents and Sensor Platform Development for Blood Biochemical Monitoring", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 27406, "first_name": "SHAWN PATRICK", "last_name": "Mulvaney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2024-12-31", "award_amount": 176283, "principal_investigator": { "id": 23781, "first_name": "Jing", "last_name": "Pan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 158, "ror": "https://ror.org/02y3ad647", "name": "University of Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 158, "ror": "https://ror.org/02y3ad647", "name": "University of Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Sepsis is one of the major healthcare problems in the United States with an annual patient care cost approaching $23 billion. Despite a substantial decrease in inpatient mortality over the past 15 years, the current epidemiology indicates a disturbing increase in the number of sepsis survivors who develop a chronic critical illness (CCI) phenotype featuring prolonged ICU stay and poor long-term outcomes. The most important clinical challenge in sepsis care today is identifying early and continuously monitor those patients with a high risk of either dying or developing CCI. Previous clinical studies show unstable sepsis patients have distinct immunologic subtypes (endotype) defined by the level and fluctuation of circulating immunomodulators over time. Unfortunately, current standard immunoassays (e.g. ELISA) provide only intermittent sampling of biomarker levels with a sample-to-result time of several hours to days, which is insufficient for timely clinical decision making using immune endotypes. The long-term goal of this research is to develop improved bioanalytical tools for predicting clinical trajectory and tailoring medical intervention based on sepsis patient’s individual pathophysiologic endotype. The overall objective in this application is to develop a biosensor platform that addresses the analytical needs of immunologic endotyping in sepsis patient care. A major technical challenge in the real-time monitoring of biomolecules is achieving fast response while maintaining low limit of detection (LOD). To resolve this conflict, the application proposes to adopt the thermal cycling process used in PCR and repurpose it for real-time protein detection. We will develop affinity reagents with temperature-selective binding properties (aim 1). This novel affinity reagent will be integrated with an ultrafast photothermal cycling sensor platform to enable sensitive and frequent biomolecular monitoring (aim 2). In aim 1 we will use in vitro selection to identify binders with temperature-sensitive affinity towards a 3- biomarker panel containing two immune-modulating proteins (i.e. IL-6 and sPD-L1) and a tissue injury indicator thrombomodulin. The optimum temperature range and binding curve for the selected reagents will be characterized. In aim 2 we will develop a sensor platform capable of frequent, multiplexed detection of IL-6, sPD-L1 and thrombomodulin in human whole blood. The research proposed is innovative because it combines novel affinity reagents and sensing mechanisms to reconcile the slow off-rate needed for sensitive detection and the fast off-rate needed for fast assay time. The proposed technology is significant because it is generally applicable to many diseases associated with uncontrolled, systematic inflammatory response, such as the management of severe COVID-19 patients and treatment for patients with cytokine release syndrome after immunotherapy. Furthermore, the successful completion of this project will form the basis for future studies, such as the clinical study on immunologic endotypes diagnostic values at different stages of sepsis, the pharmacokinetics of novel therapeutics, and the closed-loop intervention of chronic diseases.", "keywords": [ "Address", "Adopted", "Affinity", "Antibodies", "Architecture", "Binding", "Biochemical", "Biological Assay", "Biological Markers", "Biological Models", "Biological Sciences", "Biomedical Engineering", "Biosensor", "Blood", "Blood Cells", "COVID-19 patient", "COVID-19 treatment", "Caring", "Cessation of life", "Chronic", "Chronic Disease", "Clinical", "Clinical Research", "Cohort Studies", "Critical Care", "Critical Illness", "Data", "Databases", "Detection", "Development", "Devices", "Diagnosis", "Diagnostic", "Disease", "Disease Management", "Disease Progression", "Dissociation", "Drug Kinetics", "Early identification", "Engineering", "Enzyme-Linked Immunosorbent Assay", "Epidemiology", "Equilibrium", "Event", "Fluorescence", "Future", "Goals", "Healthcare", "Healthcare Systems", "Heating", "Hospitals", "Hour", "Human", "Immune", "Immune System Diseases", "Immune response", "Immunoassay", "Immunologics", "Immunomodulators", "Immunophenotyping", "Immunotherapy", "In Vitro", "Incubated", "Individual", "Inflammatory Response", "Inpatients", "Interleukin-6", "Intervention", "Knowledge", "Libraries", "Measurement", "Medical", "Microfluidic Microchips", "Mission", "Molecular", "Monitor", "Morbidity - disease rate", "National Institute of Biomedical Imaging and Bioengineering", "Oligonucleotides", "Outcome", "Patient Care", "Patients", "Performance", "Phenotype", "Physicians", "Procedures", "Process", "Property", "Proteins", "Public Health", "Reagent", "Recycling", "Research", "Sampling", "Scaffolding Protein", "Scheme", "Science", "Scientist", "Sepsis", "Septic Shock", "Signal Transduction", "Surface", "Survivors", "Technology", "Temperature", "Therapeutic", "Thrombin", "Thrombomodulin", "Time", "Transducers", "United States", "Whole Blood", "Work", "Yeasts", "absorption", "aptamer", "biomarker panel", "care costs", "clinical decision-making", "clinical predictors", "conflict resolution", "cytokine release syndrome", "design", "detection limit", "diagnostic value", "evidence base", "experience", "high risk", "immunoregulation", "improved", "individual patient", "innovation", "mortality", "multiplex detection", "nanoparticle", "novel", "novel therapeutics", "operation", "plasmonics", "predictive tools", "programmed cell death ligand 1", "rate of change", "real time monitoring", "response", "response to injury", "scaffold", "sensor", "septic patients", "severe COVID-19", "technology development", "tissue injury", "t" ], "approved": true } }, { "type": "Grant", "id": "11640", "attributes": { "award_id": "5R01MH127315-02", "title": "Cerebrospinal fluid (CSF) and peripheral markers of the neuropsychiatric sequelae of COVID-19: The Generation C-SF pregnancy study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 7203, "first_name": "Victoria", "last_name": "Arango", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2027-01-31", "award_amount": 844866, "principal_investigator": { "id": 27545, "first_name": "Maria De Las Mercedes", "last_name": "Perez Rodriguez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 7205, "first_name": "Lotje Dorothee", "last_name": "de Witte", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "A large proportion of pregnant women worldwide (21% in our CDC-funded Generation C cohort, current n=2,545) has been recently exposed to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and women of reproductive age continue to be infected despite widespread vaccination. However, the acute and subacute effects of SARS-CoV-2 infection during the vulnerable period of pregnancy and postpartum are not yet clear. Pregnancy and the postpartum are high-risk periods for coronavirus disease 19 (COVID-19) and for developing neuropsychiatric symptoms. Infections and dysregulation of inflammatory processes in the periphery and central nervous system (CNS) are thought to play a role in this vulnerability. We now know that SARS-CoV-2 causes high rates of subacute and long-term psychiatric and cognitive sequelae in the general population. There is a need to also understand the long-term effects of SARS-CoV-2 infection on mental health and cognition in the vulnerable population of pregnant and postpartum women, especially because they often are excluded from large cohort studies. We propose to study the long-term effects of prior SARS-CoV-2 infection on psychiatric and cognitive sequelae postpartum, with a mediating role of central and peripheral inflammation. We will leverage a well-powered pregnancy cohort (Generation C cohort, target n>3,000) established in April 2020 in New York, with 21% of the cohort previously exposed to SARS-CoV-2 infection to date. In a subset of this cohort (n=500), we propose to collect paired blood and cerebrospinal fluid (CSF) samples, which will provide the unique opportunity to investigate the subacute and long-term impacts of SARS-CoV-2 infection on inflammatory processes in the central nervous system (CNS). We hypothesize that prior SARS-CoV-2 infection can lead to dysregulation of peripheral and central inflammatory processes during pregnancy, and that this contributes to causing psychiatric symptoms and cognitive dysfunction in the vulnerable post-partum period. Aim 1 will characterize the subacute and long-term impact of prior exposure to SARS-CoV-2 on central and peripheral inflammation in pregnant women, including measuring SARS-CoV-2 IgG antibodies, characterizing inflammatory profiles using a high-sensitivity multiplex immunoassay for 11 inflammatory markers in CSF and blood, and examining the presence of neuronal autoantibodies. Aim 2 will examine the association between prior SARS-CoV-2 exposure, central and peripheral inflammation during pregnancy, and psychiatric symptoms postpartum. Aim 3 will examine the association between prior SARS-CoV-2 exposure, central and peripheral inflammation during pregnancy, and cognitive deficits in attention, memory and executive functioning postpartum.", "keywords": [ "2019-nCoV", "Acute", "Age", "Antibodies", "Attention", "Autoantibodies", "Autoimmune Process", "Blood", "Blood specimen", "COVID-19", "Central Nervous System", "Cerebrospinal Fluid", "Cognition", "Cognitive", "Cognitive deficits", "Cohort Studies", "Data", "Development", "Diagnostic", "Dimensions", "Exclusion", "Exposure to", "Funding", "General Population", "Generations", "Goals", "Immunoassay", "Immunoglobulin G", "Impaired cognition", "Infection", "Inflammation", "Inflammatory", "Link", "Long-Term Effects", "Longitudinal Studies", "Measures", "Mediating", "Mediator", "Memory", "Mental Health", "Neurons", "New York", "Nucleocapsid", "Outcome", "Performance", "Peripheral", "Phenotype", "Postpartum Depression", "Postpartum Period", "Postpartum Women", "Pregnancy", "Pregnant Women", "Process", "Risk Factors", "Role", "SARS-CoV-2 antibody", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "Sampling", "Vaccination", "Vulnerable Populations", "Woman", "cognitive performance", "cognitive testing", "cohort", "executive function", "fetal", "high risk", "inflammatory marker", "long term consequences of COVID-19", "neuropsychiatric sequelae of COVID-19", "neuropsychiatric symptom", "neuropsychiatry", "pathogen", "personalized medicine", "post SARS-CoV-2 infection", "postpartum outcome", "psychiatric symptom", "reproductive" ], "approved": true } }, { "type": "Grant", "id": "11641", "attributes": { "award_id": "5R01NR019831-02", "title": "A Multisite Randomized Controlled Trial of EMPOWER for Family Surrogates of Critically Ill Patients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 6036, "first_name": "Karen", "last_name": "Kehl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2026-01-31", "award_amount": 773616, "principal_investigator": { "id": 23783, "first_name": "Wendy G.", "last_name": "Lichtenthal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 27546, "first_name": "Holly Gwen", "last_name": "Prigerson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Intensive Care Units (ICUs) are stressful places fraught with grief and potentially traumatic exposures for those witnessing a critically ill family member in pain, struggling to breathe, maintain consciousness, and stay alive. Compounding their distress, family caregivers are often thrust into the position of patient “surrogate,” needing to make life-and-death decisions on the patient's behalf. We have shown that end-of-life (EoL) decision-making is compromised by elevated symptoms of distressing and disabling grief, resulting in family surrogates making suboptimal EoL choices that often prolong patient suffering, further exacerbating surrogates' grief, trauma, and regrets. The coronavirus (COVID-19) pandemic has made this bad situation worse, particularly among Black, Indigenous, and People of Color (BIPOC). Prior efforts to address the plight of these family surrogates have proved disappointing, with some significantly worsening surrogates' psychological trauma. Yet these were not psychological interventions, much less ones using psychological techniques with proven efficacy. To address these shortcomings, we developed a brief, flexibly administered intervention applying empirically supported cognitive-behavioral and acceptance-based techniques. In an R21 pilot, this intervention, EMPOWER (Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience), dramatically reduced experiential avoidance, grief, and traumatic stress, and was associated with higher rates of advance care planning, including among BIPOC. The proposed multisite, mixed-methods trial will randomize 172 family surrogates to receive EMPOWER (N=86) or a standardized supportive conversation (SC; N=86) delivered via videoconferencing. Surrogate symptoms will be assessed pre-intervention, immediately post-intervention, and 3- and 12-months post-intervention. The primary aim of this study is to compare the efficacy of EMPOWER to SC. We hypothesize that, compared to SC, EMPOWER will yield significantly greater declines in H1a. surrogate grief and posttraumatic stress (primary outcomes) and H1b. experiential avoidance, depression, regrets, and increase patients' receipt of value concordant care (secondary outcomes). The secondary aim of this study is to contextualize quantitative RCT results. H2. Qualitative interviews will provide complementary data on perceived barriers to and facilitators of symptom improvement, dissemination, and implementation, as well as insights into the impact of medical mistrust, perceived discrimination and COVID-19 on outcomes. The third aim will explore experiential avoidance as a mediator of intervention effects: H3. Reductions in experien- tial avoidance will mediate reductions in grief and posttraumatic stress. This study is expected to confirm EMPOWER's efficacy and enhance understanding of ways to improve telehealth delivery to psychologically vulnerable and historically underserved surrogates. If successful, EMPOWER will address the urgent need for effective, culturally competent interventions for distressed surrogates, which may improve critically ill patients' EoL experience in the context of extreme challenges that have been exacerbated by the COVID-19 pandemic.", "keywords": [ "Address", "Advance Care Planning", "Affect", "Anger", "Behavioral", "Bereavement", "Black race", "Black Indigenous People of Color", "Breathing", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "Caregivers", "Caring", "Cessation of life", "Cognitive", "Communication", "Confusion", "Conscious", "Coronavirus", "Critical Illness", "Data", "Decision Making", "Disease", "Disorientation", "Dissemination and Implementation", "Distress", "Emotional", "Equipment and supply inventories", "Family", "Family Caregiver", "Family health status", "Family member", "Feeling", "Goals", "Grief reaction", "Guilt", "Hospitals", "Indigenous", "Intensive Care Units", "Intervention", "Interview", "Left", "Life", "Life Experience", "Loneliness", "Mediating", "Mediation", "Mediator", "Medical", "Medical center", "Memorial Sloan-Kettering Cancer Center", "Mental Depression", "Mental Health", "Methods", "Modeling", "Numbness", "Outcome", "Pain", "Palliative Care", "Parents", "Patient Care", "Patients", "Persons", "Positioning Attribute", "Post-Traumatic Stress Disorders", "Presbyterian Church", "Psychological Techniques", "Psychological adjustment", "Quality of Care", "Race", "Randomized", "Randomized Controlled Trials", "Regrets", "Reporting", "Risk", "Role", "Severities", "Site", "Social Distance", "Standardization", "Structure", "Symptoms", "Techniques", "Thinking", "Trauma", "United States", "United States National Institutes of Health", "Videoconferencing", "comparative efficacy", "contextual factors", "cultural competence", "disease transmission", "efficacy evaluation", "end of life", "end of life care", "experience", "flexibility", "future implementation", "improved", "insight", "intervention effect", "loved ones", "meetings", "pandemic disease", "people of color", "perceived discrimination", "post intervention", "post-traumatic stress", "post-traumatic symptoms", "primary outcome", "psychologic", "psychological distress", "psychological outcomes", "psychological trauma", "psychosocial", "racial disparity", "recruit", "reduce symptoms", "resilience", "secondary outcome", "stress symptom", "symptomatic improvement", "telehealth", "traumatic stress", "treatment as usual" ], "approved": true } }, { "type": "Grant", "id": "11642", "attributes": { "award_id": "5K01HS028926-02", "title": "Adapting Guideline Implementation to Local Environments (AGILE) in Primary Care After Telehealth Expansion", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 26676, "first_name": "Tamara", "last_name": "Willis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-08", "end_date": "2027-03-31", "award_amount": 159664, "principal_investigator": { "id": 23786, "first_name": "Edmond", "last_name": "Ramly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Urgent expansion of telehealth due to the COVID-19 pandemic may have consequences for evidence based primary care, including worsening disparities in cardiovascular disease (CVD) prevention. Implementing evidence based guidelines to reverse CVD risk would prevent more than 50% of annual deaths in middle-aged US adults but is already uneven. Guideline adherence can be improved by tailoring strategies to local barriers as in Dr. Ramly’s prior work that increased follow up on blood pressure and smoking with higher gains among Black patients. Yet tailoring is too expensive and burdensome to be used in practice and is even less feasible with the rapid telehealth expansion. There is a critical need for an alternative to tailoring to enable primary care clinics to rapidly adapt how they implement CVD guidelines after telehealth expansion to avoid worsening disparities. In engineering, configurable solutions make menus of options available to avoid expensive individual tailoring. This approach could enable clinics to use known strategies to address local barriers without engaging in an expert-led individual tailoring process. Preliminary qualitative work found many barriers to optimal care with telehealth that are modifiable with known strategies. Yet configurable solutions using known strategies have not been applied in health care despite the potential to reduce cost and reduce disparities by addressing local needs. Applying this approach will require multi-stakeholder design of a configurable toolkit informed by large clinical data and tested by a pragmatic clinical trial. Dr. Ramly’s long-term goal is to become a clinical investigator in primary care leading an independent research program to improve rapid implementation of evidence based care for chronic conditions. This 5-year K01 will fill his clinical investigation training gaps with mentored research and training in large clinical data, mixed methods, and pragmatic clinical trials. As a systems engineer faculty in a clinical department, Dr. Ramly is well prepared for a successful K01 to transition from engineer collaborator to independent clinical investigator. The overall objective of this proposal is to develop and pilot a configurable toolkit for CVD prevention. Four CVD quality metrics will be targeted: blood pressure control for patients with hypertension, and aspirin, statins, and smoking cessation for patients with coronary artery disease. The specific aims are to: 1) characterize barriers to implementation of CVD guidelines in primary care after telehealth expansion, 2) develop a configurable toolkit of strategies to address local barriers, and 3) pilot test the toolkit to assess reach, effectiveness, adoption, implementation, and maintenance, including subgroup differences. Expected outcomes are an intervention addressing a critical gap in evidence based care after telehealth expansion, with preliminary data for an AHRQ R18 trial. Dr. Ramly will become an independent clinical investigator building on prior expertise in engineering and implementation science. His current and future research aims will advance AHRQ’s mission by focusing on AHRQ-relevant priority populations (chronic conditions, older adults), problem (heart health) and emphasis (primary care).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11643", "attributes": { "award_id": "5T34GM136471-02", "title": "U-RISE Program at Fayetteville State University", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 27540, "first_name": "MARIE DEBORAHGAYNELLE", "last_name": "Harton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2027-03-31", "award_amount": 322072, "principal_investigator": { "id": 23787, "first_name": "James Edward", "last_name": "Raynor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1639, "ror": "https://ror.org/03rj92e31", "name": "Fayetteville State University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1639, "ror": "https://ror.org/03rj92e31", "name": "Fayetteville State University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Program Summary The U-RISE program will be located at Fayetteville State University (FSU), which is one of the 17 constituent institutions of the University of North Carolina System and the second oldest public institution of higher education in the state. The U-RISE program will be a research training program comprised of a series of evidence-based, phased-in awareness, mentoring and developmental activities designed to help students succeed in college, and transition into biomedical, research-focused, higher degree programs upon graduation. Underrepresented minority (URM) students from biology, chemistry, forensic science, math, and computer science majors will engage in intensive research training and professional development activities beginning at the college sophomore year through their acceptance into graduate schools. Each year of program matriculation, trainees will develop new skills and experiences to become more competitive applicants for graduate schools. In light of the recent COVID-19 pandemic, alternative virtual training activities have been proposed in the event future face-to-face meetings are prohibited. Based upon institutional assessments and the previous successful design of the FSU-RISE program, this application proposes to establish a U-RISE program at FSU with an overarching goals to develop an increased talent pool of well-trained URM students in biology, chemistry, forensic science and math and computer science in which at least 90% (27 of 30) will graduate with baccalaureate degrees from FSU with at least a 3.0 GPA; and at least 75% (23 of 30) will transition into biomedical, research- focused higher degree programs within the 5 years of funding. The following three objectives are proposed to achieve these goals: 1. To enhance the academic preparation of URM trainees in biology, chemistry, forensic science, mathematics, and computer science such that each year 2. To provide meaningful research training experiences to develop a well-prepared URM trainee pool of research-ready, critical and independent thinkers for competitive entry into biomedical research-focused higher degree programs each year 3. To engage trainees in cohort-building interventions each year to enhance self-efficacy and biomedical research-focused higher degree identity Trainees will be selected through a competitive application process, which includes meeting program criteria and performing well in an interview. Longitudinal, mixed-methods formative and summative evaluations will be conducted to evaluate measures/benchmarks and program effectiveness.", "keywords": [ "Awareness", "Bachelor&apos", "s Degree", "Benchmarking", "Biology", "Biomedical Research", "COVID-19 pandemic", "Chemistry", "Degree program", "Development", "Evaluation", "Event", "Forensic Sciences", "Funding", "Future", "Goals", "Institution", "Intervention", "Interview", "Light", "Measures", "Mentors", "Methods", "North Carolina", "Phase", "Process", "Program Effectiveness", "Research", "Research Training", "Self Efficacy", "Series", "Students", "System", "Talents", "Training", "Training Activity", "Training Programs", "Underrepresented Minority", "Universities", "academic preparation", "cohort", "college", "computer science", "design", "efficacy research", "evidence base", "experience", "graduate school", "higher education", "mathematical sciences", "matriculation", "meetings", "minority trainee", "programs", "skills", "underrepresented minority student", "virtual" ], "approved": true } }, { "type": "Grant", "id": "11644", "attributes": { "award_id": "5R61AI169207-02", "title": "RNA Vaccine Innovations for TB: Targeting the Mucosa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23788, "first_name": "Jon T", "last_name": "Warren", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-22", "end_date": "2025-03-31", "award_amount": 538074, "principal_investigator": { "id": 23789, "first_name": "STEVEN GREGORY", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1031, "ror": "", "name": "HDT BIO CORPORATION", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1031, "ror": "", "name": "HDT BIO CORPORATION", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided proof of concept for effective subunit TB vaccines. Obstacles limiting commercial deployment of M72 include limited efficacy (~50% prevention of disease) and cost of goods for large-scale production. With these considerations in mind, our group developed a second-generation subunit vaccine, ID93, which consists of four protein antigens (M72 has two) formulated with a synthetic TLR4 targeted adjuvant formulation, as opposed to the natural product-based adjuvant contained in the M72 vaccine. ID93 has progressed to Phase 2 human clinical trials, with promising results and is currently in further development. Human immune responses measured against the ID93 components have been instructive and have allowed further antigen prioritization with a goal of complementing the antigens of M72. We have concurrently developed a new RNA vaccine platform - now in clinical development as a COVID-19 vaccine which may be approved in India in summer 2021 - and that induced potent cellular immunity and can be scaled in a cost-effective manner. Using a select panel of antigens, we will apply our RNA technology for inducing effective systemic and mucosal immune responses in mice and non-human primates. In addition, each of our RNA based adjuvants, TLR3 and RIG-I agonists, both being effective inducers of both innate and adaptive immune responses adds an innovative aspect. In this proposal, our innovation comes from three main areas of emphasis: First is optimization of the RNA vaccine technology by using new replicons and delivery systems. Second is applying RNA vaccination with subunit protein/adjuvant boosting, using adjuvants of known efficacy (TLR4 agonists) in comparison with novel adjuvants that signal through the TLR-3 or RIG-I pathways. Neither of these have been exploited extensively for infectious disease vaccines - particularly in the area of mucosal immunity. The third area comes from innovation in manufacturing and supply: We have novel processes for the production of TBRNA that were transferred to India (Gennova) and Brazil (CIMATEC). Gennova has already produced 1 million doses, with a target of 100 million by year-end, and has completed Phase 1 and 2 clinical trials in India. Similarly, we have acquired large- scale access to our adjuvant molecules (TLR4, TLR3, RIG-I), all synthetic, thus avoiding the intellectual property roadblock encountered with M72.", "keywords": [ "Address", "Adjuvant", "Aerosols", "Agonist", "Alphavirus", "Animals", "Antigens", "Area", "Brazil", "Businesses", "COVID-19 vaccine", "Cellular Immunity", "Clinical", "Clinical Trials", "Collaborations", "Combined Vaccines", "Communicable Diseases", "Complement", "Coupled", "Development", "Dose", "Formulation", "Generations", "Goals", "Human", "Immune response", "Immunity", "Immunization", "India", "Innate Immune Response", "Intellectual Property", "Intramuscular", "Kinetics", "Lipids", "Lung", "Measures", "Mind", "Mucosal Immune Responses", "Mucosal Immunity", "Mucous Membrane", "Mus", "Mycobacterium tuberculosis", "Mycobacterium tuberculosis antigens", "Natural Products", "Pathway interactions", "Phase", "Process", "Production", "Protein Subunits", "Proteins", "RNA", "RNA replication", "RNA vaccination", "RNA vaccine", "Recombinant Proteins", "Regimen", "Replicon", "Risk", "Route", "Safety", "Signal Transduction", "Subunit Vaccines", "System", "T-Lymphocyte", "TLR3 gene", "TLR4 gene", "Technology", "Testing", "Tuberculosis", "Tuberculosis Vaccines", "Vaccines", "adaptive immune response", "clinical development", "clinically relevant", "cost", "cost effective", "design", "disorder prevention", "immunogenicity", "improved", "in vivo", "innovation", "large scale production", "nanoparticle", "nonhuman primate", "novel", "prevent", "response", "success", "vaccination strategy", "vaccine candidate", "vaccine delivery", "vaccine development", "vaccine discovery", "vaccine distribution", "vaccine platform" ], "approved": true } }, { "type": "Grant", "id": "11645", "attributes": { "award_id": "5R01AI169239-02", "title": "Uptake, Safety and Effectiveness of COVID‐19 Vaccines during Pregnancy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-08", "end_date": "2025-03-31", "award_amount": 383326, "principal_investigator": { "id": 7298, "first_name": "Annette Karena", "last_name": "Regan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 883, "ror": "https://ror.org/029m7xn54", "name": "University of San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 883, "ror": "https://ror.org/029m7xn54", "name": "University of San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pregnant persons are at increased risk for severe COVD-19 illness compared to non-pregnant women of reproductive age, experiencing higher rates of admission to intensive care, mechanical ventilation and death. In addition to the direct impacts on the health of pregnant persons, there is growing evidence to suggest COVID-19 adversely impacts fetal and neonatal health. As of May 2021, three vaccines have been issued Emergency Use Approval in the US. However, because pregnant persons were excluded from initial Phase 3 clinical trials, data to confirm the safety and effectiveness of COVID-19 vaccination during pregnancy are lacking. Driven by this limited data, obstetric and public health governing bodies do not currently directly recommend vaccination for pregnant persons. The American College of Obstetricians and Gynecologists and the US Centers for Disease Control and Prevention (CDC) advise that COVID-19 vaccines should not be withheld from pregnant persons. As a result, the decision to vaccinate is made at the individual level, and pregnant persons express anxiety around making this decision. Additional data to inform the safety and effectiveness of COVID-19 vaccines administered during pregnancy would strengthen current clinical guidelines. Despite weak guidance, individuals are choosing to be vaccinated during pregnancy. As of 3 May 2021, 106,241 pregnant persons were reported as having received a COVID-19 vaccine through V-SAFE, the CDC’s active vaccine safety surveillance system. When surveyed, more than 50% of pregnant persons report an intention to receive a COVID-19 vaccine. Phase 2/3 clinical trial data are currently being gathered to evaluate safety and efficacy. While these clinical trial data are being collected, we have the opportunity to learn from large observational studies of pregnant persons who have chosen to be vaccinated. Leveraging existing national medical claims and electronic medical records for more than 870,000 pregnancies, we plan to conduct large-scale post-implementation cohort studies to evaluate the uptake, safety and effectiveness of COVID-19 vaccines administered during pregnancy. Completion of the proposed research will provide important epidemiological evidence on the safety and effectiveness of COVID-19 vaccination during pregnancy. This evidence will aid informed decision and policy-making around COVID-19 vaccination for pregnant persons.", "keywords": [ "2019-nCoV", "Admission activity", "Advisory Committees", "Age", "American College of Obstetricians and Gynecologists", "Anxiety", "COVID-19", "COVID-19 diagnosis", "COVID-19 impact", "COVID-19 vaccination", "COVID-19 vaccine", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Clinical", "Clinical Trials", "Cohort Studies", "Computerized Medical Record", "Data", "Databases", "Decision Making", "Discipline of obstetrics", "Disease", "Effectiveness", "Electronic Health Record", "Eligibility Determination", "Emergency Situation", "Ensure", "Epidemiology", "Event", "Exclusion", "FDA Emergency Use Authorization", "Fetal health", "Goals", "Guidelines", "Health", "Health Personnel", "Immunization", "Individual", "Infant", "Infant Health", "Infection", "Intensive Care", "Intention", "Learning", "Link", "Maternal Health", "Mechanical ventilation", "Medical", "Mothers", "Nature", "Observational Study", "Outcome", "Participant", "Passive Immunity", "Perinatal", "Perinatal mortality demographics", "Persons", "Phase", "Phase II/III Clinical Trial", "Phase III Clinical Trials", "Planned Pregnancy", "Policies", "Policy Making", "Population", "Population Group", "Pregnancy", "Pregnancy loss", "Premature Birth", "Probability", "Public Health", "Recommendation", "Reporting", "Research", "Risk", "Risk Factors", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "Safety", "Special Event", "Surveys", "System", "Time", "Update", "Vaccinated", "Vaccination", "Vaccines", "Woman", "adverse outcome", "adverse pregnancy outcome", "care providers", "experience", "fetal", "high risk", "implementation evaluation", "influenza virus vaccine", "interest", "maternal outcome", "neonatal health", "neonatal outcome", "neonate", "new technology", "policy implication", "policy recommendation", "post SARS-CoV-2 infection", "post implementation", "pregnant", "prevent", "programs", "reproductive", "severe COVID-19", "sociodemographics", "systematic review", "unvaccinated", "uptake", "vaccination outcome", "vaccination strategy", "vaccine acceptance", "vaccine safety", "variants of concern" ], "approved": true } }, { "type": "Grant", "id": "11646", "attributes": { "award_id": "5T34GM145505-02", "title": "U-RISE at PVAMU", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 27540, "first_name": "MARIE DEBORAHGAYNELLE", "last_name": "Harton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2027-03-31", "award_amount": 291506, "principal_investigator": { "id": 27547, "first_name": "E GLORIA CLAUDETTE", "last_name": "REGISFORD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1640, "ror": "", "name": "PRAIRIE VIEW AGRI & MECH UNIVERSITY", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "URISE at PVAMU PI/PD: Regisford The increasing need for a well-trained STEM workforce, made more poignant during this COVID-19 pandemic, also requires a diverse population to meet the future needs and challenges in the biomedical sciences. An Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program will reach a large racial and ethnic underrepresented (UR) population with disadvantaged socio-economic backgrounds and first-generation college students at Prairie View A&M University (PVAMU), a historically black university. Moreover, PVAMU's promotion of undergraduate engagement in research, and its established collaborations with surrounding research- intensive universities, provide a robust learning environment that will strongly support a U-RISE program. Although student enrollment in biomedical science disciplines such as Biology and Chemistry are relatively high, less than 10% declare an interest in graduate school; a conundrum that may be due to lack of exposure and preparation for the rigors of graduate school. Therefore, the overarching goal of this proposed U-RISE program is to enhance student participation and preparation in the biomedical sciences for matriculation into highly competitive PhD programs and ultimately, a biomedical science research career. This goal will be accomplished by the following specific objectives: (1) Provide an enriched interdisciplinary research culture that exposes all U-RISE trainees to hands-on research for three consecutive years; (2) Enhance the academic curriculum that fosters advancement of 80% of U-RISE at PVAMU trainees to a biomedical science graduate program and (3) Create a nurturing learning community by engaging U-RISE at PVAMU trainees in a multidimensional mentoring program, that will lead to improved retention (90% of U-RISE trainees) and graduation rate (90% of U-RISE trainees). Program elements will include professional skills development of all U- RISE trainees to enhance their competitiveness. We have built a multidisciplinary team of faculty, research professors/scientists, and external collaborators to create a nurturing and stimulating culture that will evoke evidence-based student support and motivation practices. Each year, four sophomores will be selected to join the U-RISE at PVAMU program. Selection of U-RISE trainees will be based on the following criteria: the students' academic record, member of a racial and ethnic UR population, a declared major in a biomedical science discipline, and a desire to attend graduate school in the biomedical sciences. The expected outcomes are (1) an increase in the number of students who become engaged in biomedical science research; (2) an extensive academic preparation of U-RISE at PVAMU trainees for matriculation into a competitive graduate program within one year after graduation; and (3) the creation of a replicable, transportable, evidence-based model that promotes preparation of undergraduates from UR populations for biomedical science research careers. Ultimately, the U-RISE at PVAMU program will contribute to increased diversity in the biomedical sciences workforce.", "keywords": [ "Biology", "COVID-19 pandemic", "Chemistry", "Collaborations", "Dimensions", "Discipline", "Doctor of Philosophy", "Educational Curriculum", "Elements", "Enrollment", "Ethnic Origin", "Faculty", "First Generation College Students", "Fostering", "Future", "Goals", "Graduation Rates", "Historically Black Colleges and Universities", "Interdisciplinary Study", "Mentors", "Modeling", "Motivation", "Outcome", "Population Heterogeneity", "Preparation", "Race", "Research", "Research Training", "STEM career", "Science", "Scientist", "Students", "Training", "Underrepresented Populations", "Universities", "academic preparation", "career", "community engagement", "educational atmosphere", "evidence base", "graduate school", "hands on research", "improved", "interest", "learning community", "matriculation", "member", "multidisciplinary", "professor", "programs", "skill acquisition", "socioeconomic disadvantage", "student participation", "undergraduate research", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "11647", "attributes": { "award_id": "5F31AT011988-02", "title": "Exploring the Potential of Natural Products to Combat COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26174, "first_name": "Patrick Colby", "last_name": "Still", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2024-12-31", "award_amount": 47694, "principal_investigator": { "id": 26175, "first_name": "Caitlin Jaime", "last_name": "Risener", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "As of August 2021, the coronavirus disease COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has infected more than 200 million people across the globe, causing more than 600,000 deaths in the USA and 4.2 million worldwide. Though vaccines have become available, vaccinated individuals can still spread the disease to unvaccinated and vulnerable populations. As vaccination rates in the United States remain low, emerging variants that may evade the vaccine are a new risk. Identifying novel preventative agents from traditional medicine could lead to the development of a readily available, cost-effective, and safe dietary intervention against COVID-19. During the pandemic, individuals have turned to herbal supplements to prevent COVID-19. There are published in silico studies and a few in vitro studies on these extracts, but the science to support natural products’ (NPs) use to prevent viral infection is still incomplete. The Quave Natural Product Library (QNPL) is a collection of over 2,000 botanical and fungal extracts, including the 40 most used natural supplements in the USA. Viral entry, in which SARS-CoV-2 attaches to the Angiotensin-Converting Enzyme 2 (ACE2) cell surface receptor found on endothelial cells, pneumocytes (type 1 and 2), and ciliated bronchial epithelial cells, presents an attractive option for preventatives. I have screened 2,000 extracts from the QNPL against SARS-CoV- 2 pseudotyped virus system to test which extracts inhibit viral entry. Mammalian cell cytotoxicity assays measuring Lactate Dehydrogenase (LDH) formation were run in parallel to ensure inhibition was not due to cell death. This proposal employs a multi-faceted approach to identify agents with direct-acting antiviral properties using a one-of-a-kind natural product library. Three extracts with potent bioactivity as direct-acting antiviral agents without apparent toxicity were selected after screening the QNPL. Bioassay guided fraction coupled to LC- MS/MS molecular networking analysis will be used for the identification of compounds with direct-acting antiviral activity. Compounds will be further isolated using preparative HPLC and structurally elucidated by NMR and X- crystallography to determine the absolute structure of the viral inhibitor. The fractions and isolated compounds will be tested across emerging variants in relevant cell lines and in live virus to further understand activity. Additionally, I will undertake mechanism of action studies utilizing biolayer interferometry and ELISA assays. These studies will result in the identification of NPs with the potential to block SARS-CoV-2 viral entry in relevant human cells, enhancing understanding of the preventative value of plant NPs for COVID-19 and other viruses. This will enable formulation of a bioactive dietary supplement, prioritization of leads for a medicinal chemistry campaign, and identification of tool compounds to query these pathways.", "keywords": [ "2019-nCoV", "A549", "ACE2", "Antiviral Agents", "Binding", "Biological Assay", "Biological Sciences", "Botanicals", "COVID-19", "COVID-19 prevention", "COVID-19 treatment", "Cell Death", "Cell Line", "Cell Surface Receptors", "Cell model", "Cells", "Cessation of life", "Chemicals", "China", "Chromatography", "Ciliated Bronchial Epithelial Cell", "Collaborations", "Collection", "Communicable Diseases", "Contracts", "Coupled", "Crystallography", "Data", "Development", "Diet", "Dietary Intervention", "Disease", "Dose", "Edible Plants", "Endothelial Cells", "Ensure", "Enzyme-Linked Immunosorbent Assay", "Epithelial Cells", "Ethnobotany", "Exhibits", "Formulation", "Fractionation", "Goals", "Health Care Costs", "Health Professional", "Herbal supplement", "High Pressure Liquid Chromatography", "Human", "Immune response", "In Vitro", "Indigenous", "Individual", "Infection", "Inflammatory", "Interferometry", "Lactate Dehydrogenase", "Lentivirus", "Libraries", "Luciferases", "Lung", "Mammalian Cell", "Measures", "Medicinal Plants", "Medicine", "Modeling", "Molecular", "Natural Compound", "Natural Products", "Natural Supplement", "Pathway interactions", "Persons", "Pharmaceutical Chemistry", "Pharmacognosy", "Plants", "Plaque Assay", "Population", "Process", "Property", "Province", "Publishing", "Recording of previous events", "Reporter", "Research", "Resistance", "Resolution", "Resources", "Risk", "Running", "SARS-CoV-2 infection", "SARS-CoV-2 inhibitor", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Safety", "Science", "Serial Passage", "Severity of illness", "Standardization", "Structure", "Surface", "System", "Techniques", "Testing", "Therapeutic", "Toxic effect", "Traditional Medicine", "United States", "Vaccinated", "Vaccination", "Vaccinee", "Vaccines", "Variant", "Viral", "Viral Physiology", "Virus", "Virus Diseases", "Virus Inhibitors", "Vulnerable Populations", "X-Ray Crystallography", "clinically relevant", "combat", "coronavirus disease", "cost effective", "cytotoxicity", "dietary", "dietary supplements", "efficacy validation", "high throughput screening", "in silico", "insight", "novel", "pandemic disease", "pneumocyte", "prevent", "receptor", "receptor binding", "repository", "screening", "secondary metabolite", "symptom treatment", "tool", "unvaccinated", "vaccine access", "vaccine hesitancy", "viral entry inhibitor" ], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1419, "count": 14184 } } }